GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (NAS:SYBX) » Definitions » 5-Year Yield-on-Cost %

SYBX (Synlogic) 5-Year Yield-on-Cost % : 0.00 (As of Mar. 14, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Synlogic 5-Year Yield-on-Cost %?

Synlogic's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Synlogic's 5-Year Yield-on-Cost % or its related term are showing as below:



SYBX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Synlogic's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Synlogic's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synlogic's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synlogic's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Synlogic's 5-Year Yield-on-Cost % falls into.



Synlogic 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Synlogic is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Synlogic  (NAS:SYBX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Synlogic 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Synlogic's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Synlogic Business Description

Traded in Other Exchanges
Address
301 Binney Street, Suite 402, Cambridge, MA, USA, 02142
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Executives
Antoine Awad officer: Chief Operating Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Vangsted Jensen officer: Chief Financial Officer 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Aoife Brennan officer: Chief Medical Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Lisa Kelly-croswell director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Michael F. Burgess director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Richard P Shea director C/O MOMENTA PHARMACEUTICALS, INC., 43 MOULTON STREET, CAMBRIDGE MA 02138
Gregg Beloff officer: See Remarks C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Richard J. Riese officer: Chief Medical Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Ginkgo Bioworks, Inc. 10 percent owner 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Scott Eric Plevy officer: Chief Scientific Officer 301 BINNEY STREET, #402, C/O SYNLOGIC, INC., CAMBRIDGE MA 02142
Paul Francis Miller officer: Chief Scientific Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Patricia N. Hurter director C/O SYNLOGIC, INC., 301 BINNEY ST., SUITE 402, CAMBRIDGE MA 02142
Andrew Gengos officer: See Remarks 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Todd Shegog officer: See Remarks 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139

Synlogic Headlines

From GuruFocus

Synlogic Inc Corporate Update Transcript

By GuruFocus Research 02-09-2024

Synlogic Inc at Jefferies Healthcare Conference Transcript

By GuruFocus Research 02-09-2024

Q2 2020 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2022 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2020 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2019 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2021 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024